Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway

Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis

(2023) Alison R. McClean et al.   ARTHRITIS CARE & RESEARCH

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

(2022) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

(2022) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey

(2021) Allison R. Kolbe et al.   BIODRUGS

Shift From Adalimumab Originator to Biosimilars in Denmark

(2020) Thomas Bo Jensen et al.   JAMA Internal Medicine

Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives

(2020) Joshua F. Baker et al.   Arthritis & Rheumatology

An Opportunity Missed: Biosimilars in the United States

(2020) Guro L. Goll et al.   Arthritis & Rheumatology

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update

(2020) Laure Gossec et al.   ANNALS OF THE RHEUMATIC DISEASES

Use of biosimilars in inflammatory bowel diseases: A survey among the clinicians members of the Italian Group for the Study of Inflammatory Bowel Disease (IGIBD)

(2020) Angelo Viscido et al.   DIGESTIVE AND LIVER DISEASE

Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice

(2020) Virginia Solitano et al.   Expert Review of Clinical Immunology

Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Open-label extension of the NOR-SWITCH trial

(2019) Guro L. Goll et al.   JOURNAL OF INTERNAL MEDICINE

Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study

(2019) Sella A Provan et al.   RHEUMATOLOGY

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

(2018) Bente Glintborg et al.   ANNALS OF THE RHEUMATIC DISEASES

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

(2017) Kristin K Jørgensen et al.   LANCET

Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons

(2017) Till Uhlig et al.   RHEUMATOLOGY

Rheumatoid arthritis

(2016) Josef S Smolen et al.   LANCET

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

(2015) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Biosimilars: the science of extrapolation

(2014) M. Weise et al.   BLOOD

Biosimilars to treat inflammatory arthritis: the challenge of proving identity

(2013) Jonathan Kay et al.   ANNALS OF THE RHEUMATIC DISEASES

Biosimilars in rheumatology: the wind of change

(2013) Christian K Schneider   ANNALS OF THE RHEUMATIC DISEASES

Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010

(2013) Anna-Birgitte Aga et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

(2013) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

(2013) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

Inequities in access to biologic and synthetic DMARDs across 46 European countries

(2013) Polina Putrik et al.   ANNALS OF THE RHEUMATIC DISEASES

The role of biosimilars in the treatment of rheumatic diseases

(2012) Thomas Dörner et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES